Monday, March 05, 2018 10:15 PM ET
Insider buy at La Jolla Pharmaceutical Co (LJPC) Extends the Trend of purchases over Last Quarter
An insider — Kevin C Tang, 10% Owner and Director — purchased 40,000 shares of La Jolla Pharmaceutical Co having a market value of approximately $1,202,527 today, as revealed in a form 4 document filed with the SEC. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been buys resulting in the acquisition of 377,000 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net purchases of 417,000 shares and have averaged 104,250 shares per transaction over this time period.
Over the last 90 days, the number of insider buy/sell trades at La Jolla Pharmaceutical Co is greater than its 285-company peer group average. The Bio Therapeutic Drugs peer group saw 324 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares traded per transaction by La Jolla Pharmaceutical Co insiders is lower than its peers. Within the peer group there were 27,547,215 shares purchased and 14,419,372 shares sold with company insiders purchasing 63,727 shares on average over this time period.
The data sourced in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.